• Autophagy and Cementoblast Mineralization Under Compression

  2026-10-08

  A 2022 Research Square preprint links compression-related impairment of cementoblast mineralization to reduced autophagy and identifies a periostin/β-catenin signaling axis as a mechanistic connection. Its combined cell, transcriptomic, and mouse-model evidence suggests that autophagy is relevant to cementum repair, while the preclinical design limits direct clinical translation.

• Panobinostat, Calcineurin, and Multiple Myeloma

  2026-10-08

  The reference study identifies the calcineurin catalytic subunit PPP3CA as a potentially actionable vulnerability in multiple myeloma and links its degradation to panobinostat activity. Its findings support further investigation of calcineurin-directed combinations, particularly in disease associated with bortezomib resistance, while remaining preclinical and subject to important translational limitations.

• Protease Inhibitor Cocktail: Evidence and Limits

  2026-10-07

  This overview examines how an EDTA-free Protease Inhibitor Cocktail is positioned for plant protein preservation, how inhibitor classes relate to protein degradation, and why findings from a 2025 TBK1–itaconic acid study provide mechanistic context rather than direct validation. The evidence, applicability boundaries, and unresolved questions are separated from supplier claims.

• From Control Liposomes to Translational Confidence

  2026-10-07

  PBS Liposomes can strengthen macrophage depletion studies by separating carrier uptake from clodronate-driven effects. This thought-leadership analysis connects that control logic with structural insights into TRPM3 regulation while defining the limits of cross-domain translation.

• Protease Inhibition as a Translational Design Variable

  2026-10-06

  Protein preservation is more than a sample-preparation concern: it shapes the biological story that proteomics, structural biology, and translational assays can tell. This article connects protease inhibition in protein extraction with the mechanistic lessons of recent Lassa virus spike research, while defining the evidence boundaries for an MS-compatible Protease Inhibitor Cocktail.

• Doxycycline: Mechanism, Evidence & Research Limits

  2026-10-06

  Doxycycline is a tetracycline antibiotic with established antimicrobial activity and reported metalloproteinase inhibition. Current cancer research supports mechanistic investigation, but an MMP-2-responsive breast cancer delivery study did not test doxycycline itself.

• AMD-070 Hydrochloride: CXCR4 Research Evidence

  2026-10-05

  This overview evaluates mavorixafor hydrochloride, also called AMD-070 hydrochloride, as a CXCR4 antagonist through the lens of the supplied evidence. It separates supplier-described mechanisms and clinical relevance from peer-reviewed findings, compares the compound’s proposed research context with independent work on ischemia and tissue injury, and outlines important limits on interpretation.

• Bazedoxifene: Evidence and Research Context

  2026-10-05

  Bazedoxifene is a selective estrogen receptor modulator established in osteoporosis treatment research and now being evaluated as a possible inhibitor of IL-6/GP130 signaling. This overview compares its estrogen-receptor and anticancer evidence, clarifies what remains preclinical, and outlines major translational limitations without providing experimental procedures.

• 3X FLAG Peptide: From Tagging to Translation

  2026-10-04

  How the 3X (DYKDDDDK) Peptide can support evidence-driven protein research, from mechanistic investigation to translational assay strategy, while keeping claims and limitations in view.

• V5 Epitope Tag Peptide: Evidence and Limits

  2026-10-03

  The V5 Epitope Tag Peptide is a defined 14-residue antigenic sequence used to support antibody-based detection of recombinant proteins. Evidence supports V5-directed antibody applications, but the commercial peptide itself does not replace genetic fusion, antibody validation, or assay-specific controls.

• Angiotensin (1-7): Applied Research Workflows

  2026-10-02

  Build reproducible cell, enzyme, and animal studies around a sequence-defined Mas receptor agonist with clear handling and assay controls. This guide connects Angiotensin (1-7) biology to ACE2 assay logic, renal fibrosis, inflammation, and translational model selection while separating literature-backed conditions from practical starting points.

• V5 Epitope Tag Peptide: Workflow Guide

  2026-10-01

  Use the V5 Epitope Tag Peptide as a defined antigen, competition control, and assay-standardization tool for recombinant protein detection. This guide connects routine Western blot and immunoprecipitation workflows with the fast-dissociating antibody strategy reported for dynamic single-molecule imaging.

• FLAG tag Peptide in Cardiovascular Assays

  2026-10-01

  The FLAG tag Peptide (DYKDDDDK) can strengthen recombinant protein detection and purification workflows for mechanistic cardiovascular research. This article connects tag design, gentle competitive elution, and assay interpretation to the ceramide–CYSLTR2/P2RY6 findings reported in Nature.

• USP36–Snail1 Control of Ribosome Stress in Cancer

  2026-09-30

  The reference study identifies a JNK–USP36–Snail1 mechanism that enables solid tumor cells to preserve nucleolar ribosome biogenesis during ribotoxic stress. Its findings explain why homoharringtonine can be effective in leukemia yet less active against solid tumors, and provide a rationale for combining ribosome inhibition with pathway-directed interventions.

• Moxidectin: From Anthelmintic to Assay Design

  2026-09-30

  Moxidectin is a macrocyclic lactone anthelmintic with established veterinary applications and emerging antifungal combination potential. This article explains how its Candida–polyene mechanism should shape assay design, controls, interpretation, and translational decisions.

7887 records 1/526 page Next 12345 下5页 Last page